Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423787 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety/Tolerability of Ragweed MATA MPL
A Phase 3 study, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 993
- Enrollment target
NCT00423787: Completed Phase 3 study, sponsored by Allergy Therapeutics.
NCT00423787 is a Phase 3 study that has completed, run by Allergy Therapeutics. The registered enrollment target is 993 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00423787, a Phase 3 study, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 993 participants
- Enrollment target
Study Summary
Ragweed MATAMPL has been developed by Allergy Therapeutics to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting ragweed pollens causing rhinitis and/or conjunctivitis with or without mild to moderate asthma bronchiale. The purpose of this study is to compare the efficacy of Ragweed MATAMPL versus placebo in ragweed-allergic subjects following 4 subcutaneous injections of study medication administered before the start of the 2007 ragweed pollen season
Interventions
- BIOLOGICAL Ragweed MATA MPL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 993 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
What the finished NCT00423787 record still lists
NCT00423787 is an interventional study that assigns participants to a tested intervention. The registered 993 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% higher).
The record links to 0 conditions, and to 1 intervention - of which Ragweed MATA MPL is the first listed.
NCT00423787 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00423787 about?
NCT00423787 is a clinical study titled "Efficacy and Safety/Tolerability of Ragweed MATA MPL". Ragweed MATAMPL has been developed by Allergy Therapeutics to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting ragweed pollens causing rhinitis and/or conjunctivitis with or without mild to moderate asthma bronchiale. The purpose of this ...
What is the current status of trial NCT00423787?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 993 participants. The study started on 2007-03. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00423787?
The interventions under investigation include: Ragweed MATA MPL (BIOLOGICAL).
Who is sponsoring clinical trial NCT00423787?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00423787's enrollment target sits among peer trials
993 314th of 2000 higher than 1,687 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05437575 · 994 participants · Phase 3
Prehospital Analgesia INtervention Trial (PAIN)
- NCT06671704 · 994 participants · NA
GC-PRO Intervention
- NCT05987241 · 992 participants · Phase 2
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
- NCT07005024 · 996 participants · Phase 3
DOAC - Dosing Options in AntiCoagulation Prophylaxis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia